Corporate Presentation April 2025 1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin ...

1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin and our other drug programs, the ...

Lexicon Pharmaceuticals (LXRX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Okay. Thanks for tuning in to the next session. I'm Andrew Tsai, senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today. To my direct left, Mike Exton, CEO. To his left, Craig Granowitz, CMO. And to Craig's left is Scott Coyante, CFO. Welcome, all of you. Speaker1 Yeah. Thank you. How's it So Speaker0 maybe spend a couple minutes talking about the Lexicon story, what you're working on, ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Lisa DeFrancesco - SVP of Investor Relations & Corporate CommunicationsMike Exton - CEO & DirectorScott Coiante - SVP and CFOAndrew Tsai - SVPCraig Granowitz - SVP & Chief Medical OfficerYigal Nochomovitz - DirectorLander Egaña-Gorroño - Senior Associate, Biotech Equity Research Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystYasmeen Rahimi - Sr. Research Analyst Opera ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Welcome to the Lexicon Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, 05/13/2025. I will now turn the call over to Lisa DiFrancesco, SVP, Investor Relations and Corporate Communications for ...

Core Insights - Lexicon Pharmaceuticals has made significant progress in 2025, focusing on R&D and achieving key milestones, including an exclusive licensing agreement with Novo Nordisk for LX9851 and positive results from the Phase 2b PROGRESS study for pilavapadin [1][3][4] Financial Performance - Revenues for Q1 2025 increased to $1.3 million from $1.1 million in Q1 2024, primarily driven by product sales of INPEFA® (sotagliflozin) [9] - Research and development expenses rose to $15.3 million in Q1 2025 from $14.4 million in Q1 2024, reflecting ongoing investments in clinical trials [10] - Selling, general and administrative expenses decreased significantly to $11.6 million in Q1 2025 from $32.1 million in Q1 2024 due to strategic repositioning and reduced marketing efforts [11] - The net loss for Q1 2025 was $25.3 million, or $0.07 per share, compared to a net loss of $48.4 million, or $0.20 per share, in Q1 2024 [12] Pipeline Developments - Pilavapadin (LX9211) is advancing towards Phase 3 development for diabetic peripheral neuropathic pain (DPNP), with the 10 mg dose showing meaningful pain reduction in the Phase 2b PROGRESS study [7][4] - LX9851, a novel oral candidate for obesity, is in preclinical development, with Lexicon eligible for up to $1 billion in milestone payments from Novo Nordisk [7][3] - The SONATA-HCM study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is underway, targeting 500 patient enrollments [6][7] Cash Position - As of March 31, 2025, Lexicon had $194.8 million in cash and investments, down from $238.0 million at the end of 2024, partly due to severance payments related to strategic changes [13][20]

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing a ...